Efficacy and safety of GLP ‐1 receptor agonists and SGLT2 inhibitors as adjuncts to insulin in type 1 diabetes: Systematic review and meta‐analysis

Key Points

Adjunctive GLP-1 receptor agonists and SGLT2 inhibitors provide modest clinical improvements.
Increased risk of diabetic ketoacidosis is noted with SGLT2-based therapies.
This systematic review and meta-analysis assess safety and efficacy of these interventions.
Larger long-term trials are necessary to optimize the use of these therapies.

Abstract

Adjunctive GLP-1RAs and SGLT2is provide modest clinical improvements in adults with type 1 diabetes. These benefits must be balanced against class-specific safety concerns, especially the increased risk of DKA with SGLT2-based therapies. Larger, long-term trials are needed to define their optimal use in routine care.

Read Full Paperexternally

Bookmark

View Full Paper

Cite This Study

Abdel‐Rahman et al. (Wed,) studied this question.

synapsesocial.com/papers/69a75c7ac6e9836116a25660 https://doi.org/https://doi.org/10.1111/dom.70506

Bookmark

View Full Paper